Gilead (GILD) and Kite (KITE)

In early October of 2017, Gilead Sciences, Inc. (GILD) merged with Kite Pharma, Inc. (KITE) for $180 per share, net to the seller in cash.
This can be entered into the accounting system as a sale of all shares held by the club, for whatever amount of money the club received. If the club was charged any sort of fee in connection with the merger, that fee can be entered as part of the sale of KITE.